Over-sulfated chondroitin sulfate derivatives induce osteogenic differentiation of hMSC independent of BMP-2 and TGF-β1 signalling

Journal of Cellular Physiology

Volumn 228, Issue 2, 2013, Pages 330-340

  Büttner, Marianne ^a   Möller, Stephanie ^b   Keller, Mario ^c   Huster, Daniel ^c   Schiller, Jürgen ^c   Schnabelrauch, Matthias ^b   Dieter, Peter ^a   Hempel, Ute ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b BIOMATERIALS DEPARTMENT   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; CHONDROITIN 4' SULFATE; CHONDROITIN 6' SULFATE; CHONDROITIN SULFATE; COLLAGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MESENCHYMAL STROMA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SULFATION;

ADULT; ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; CHONDROITIN SULFATES; COLLAGEN; FEMALE; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS; PROTEIN KINASES; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84868007094     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24135     Document Type: Article

References (62)

1. Arnott JA, Nuglozeh E, Rico MC, Arango-Hisijara I, Odgren PR, Safadi FF, Popoff SN. 2007. Connecive tissue growth factor (CTGF/CCN2) is a downstream mediator for TGF-β1-induced extracellular matrix production in osteoblasts. J Cell Physiol 210:843-852.
2. Berger C, Montag C, Berndt S, Huster D. 2011. Optimization of Escherichia coli cultivation methods for high yield neuropeptide Y receptor type 2 production. Protein Expr Purif 76:25-35.
3. Bismar H, Klöppinger T, Schuster EM, Balbach S, Diel I, Ziegler R, Pfeilschifter J. 1999. Transforming growth factor beta (TGF-beta) levels in the conditioned media of human bone cells: Relationship to donor age, bone volume, and concentration of TGF-beta in human bone matrix in vivo. Bone 24:565-569.
4. Canalis E, Economides AN, Gazzerro E. 2003. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24:218-235.
5. Celeste AJ, Iannazzi JA, Taylor RC, Hewick RM, Rosen V, Wang EA, Wozney JM. 1990. Identification of transforming growth factor beta family members present in bone-inductive protein purified from bovine bone. PNAS 87:9843-9847.
6. Chen D, Zhao M, Mundy GR. 2004. Bone morphogenetic proteins. Growth Factors 22:233-241.
7. Chen G, Deng C, Li Y-P. 2012. TGF-β and BMP signalling in osteoblast differentiation and bone formation. Int J Biol Sci 8:272-288.
8. Choi YJ, Lee JY, Park JH, Park JB, Suh JS, Choi YS, Lee SJ, Chung C-P, Park YJ. 2010. The identification of a heparin binding domain peptide from bone morohogenetic protein-4 and its role on osteogenesis. Biomaterials 31:7226-7238.
9. Curie GA. 1981. Platelet derived growth-factor requirement for in vitro proliferation of normal and malignant mesenchymal cells. Br J Cancer 43:335-343.
10. Dejima K, Kanai MI, Akiyama T, Levings DC, Nakato H. 2011. Novel contact-dependent bone morphogenetic protein (BMP) signaling mediated by heparan sulfate proteoglycans. J Biol Chem 286:17103-17111.
11. Fischer U, Hempel U, Becker D, Bierbaum S, Scharnweber D, Worch H, Wenzel K-W. 2003. Transforming growth factor beta1 immobilized adsorptively on Ti6Al4V and collagen type I coated Ti6Al4V maintains its biological activity. Biomaterials 24:2631-2641.
12. Fromigué O, Marie PJ, Lomri A. 1998. Bone morphogenetic protein-2 and transforming growth factor-β2 interact to modulate human bone marrow stromal cell proliferation and differentiation. J Cell Biochem 68:411-426.
13. Gallagher JT, Turnbull JE. 1992. Heparan sulphate in the binding and activation of basic fibroblast growth factor. Glycobiol 2:523-528.
14. Guicheux J, Lemonier J, Ghayor C, Suzuki A, Palmer C, Caverzasio J. 2003. Activation of p38 mitogen-activated protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res 18:2060-2068.
15. Guo X, Wang X-F. 2009. Signaling cross-talk between TGF-β/BMP and other pathways. Cell Res 17:71-88.
16. Han D, Liu W, Ao Q, Wang G. 2008. Optimal delivery systems for bone morphogenetic proteins in orthopedic applications should model initial tissue repair structures by using a heparin-incorporated fibrin-fibronectin matrix. Med Hypotheses 71:374-378.
17. Heldin CH, Miyazono K, ten Dijke P. 1997. TGF-beta signaling from cel membrane to nucleus through Smad proteins. Nature 390:465-471.
18. Hempel U, Hefti T, Kalbacova M, Wolf-Brandstetter C, Dieter P, Schlottig F. 2010. Response of osteoblast-like SAOS-2 cells to zirconia ceramics with different surface topographies. Clin Oral Impl Res; 21:174-181.
19. Hempel U, Hintze V, Möller S, Schnabelrauch M, Scharnweber D, Dieter P. 2012. Artificial extracellular matrices composed of collagen I and sulfated hyaluronan with adsorbed transforming growth factor β1 promote collagen synthesis of human mesenchymal stromal cells. Acta Biomat 8:659-666.
20. Hillger F, Herr G, Rudolph R, Schwarz E. 2005. Biophysical comparison of BMP-2, pro-BMP-2, and the free pro-peptide reveals stabilization of the pro-peptide by the mature growth factor. J Biol Chem 280:14974-14980.
21. Irie A, Habuchi H, Kimata K, Sanai Y. 2003. Heparan sulfate is requred for bone morphogenetic protein-7 signaling. Biochem Biophys Res Comm 308:858-865.
22. Jackson RA, Murali S, van Wijnen AJ, Stein GS, Nurcombe V, Cool SM. 2007. Heparan sulfate regulates the anabolic activity of MC3T3-E1 preosteoblast cells by induction of Runx2. J Cell Physiol 210:38-50.
23. Jiao X, Billings PC, O'Connell MP, Kaplan FS, Shore EM, Glaser DL. 2007. Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. J Biol Chem 282:1080-1086.
24. Johnson MR, Boerckel JD, Dupont KM, Guldberg RE. 2011. Functional restoration of critically sized segmantal defects with bone morphogenetic protein-2 and heparin treatment. Clin Orthop Relat Res 469:3111-3117.
25. Kanzaki S, Takahashi T, Kanno T, Ariyoshi W, Shinmyouzu K, Tujisawa T, Nishihara T. 2008. Heparin inhibits BMP-2 osteogenic bioactivity by binding to both BMP-2 and BMP receptor. J Cell Physiol 216:844-850.
26. Kawano M, Ariyoshi W, Iwanaga K, Okinaga T, Habu M, Yoshiola I, Tominaga K, Nishihara T. 2011. Mechanism involved in enhancement of osteoblast differentiation by hyaluronic acid. Bioche Biophys Res Comm 405:575-580.
27. Khan S, Nelson MS, Pan C, Gaffney PM, Gupta P. 2008. Endogenous heparan sulfate and heparin modulate bone morphogenetic protein-4 signaling and activity. Am J Cell Physiol 294:C1387-C1397.
28. Kim M, Choe S. 2011. BMPs and their clinical potentials. BMB Reports 44:619-634.
29. Koike T, Izumikawa T, Tamura J, Kitagawa H. 2012. Chondroitin sulfate-E fine-tunes osteoblast differentiation via ERK1/2, Smad3 and Smad1/5/8 signaling by binding to N-cadherin and cadherin-11. Biochem Biophys Res Comm 420:523-529.
30. Kozawa O, Hatakeyama D, Uematsu T. 2002. Divergent regulation by p44/p42 MAP kinase and p38 MAP kinase of bone morphogenetic protein-4-stumulated osteocalcin synthesis in osteoblasts. J Cell Biochem 84:583-589.
31. Kuo W-J, Digman MA, Lander AD. 2010. Heparan sulfate acts as a bone morphogenetic protein coreceptor by facilitating ligand-induced receptor-oligomerization. Mol Biol Cell 21:4028-4041.
32. Lee JY, Choo JE, Choi YS, Lee KY, Min DS, Seol YJ, Lee SJ, Jo IH, Chung CP, Park YJ. 2007. Characterization of the surface immobilized dynthetic haparin binding domain derived from homan fibroblast growth factor-2 and its effect on osteoblast differentiation. J Biomed Mater Res A 83:970-979.
33. Ling L, Dombrowski C, Foong KM, Haupt LM, Stein GS, Nurcombe V, van Wijnan AJ, Cool SM. 2010. Synergism between Wnt3a and heparin enhances osteogenesis via phosphoinositide 3-kinase/Akt/RUNX2 pathway. J Biol Chem 285:26233-26244.
34. Lynch MP, Capparelli C, Stein JL, Stein GS, Lian JB. 1998. Apoptosis during bone-like tissue development. J Cell Biochem 68:31-49.
35. Macri L, Silverstein D, Clark R. 2007. Growth factor binding to the pericellular matrix and its importance in tissue engineering. Adv Drug Deliv Rev 59:1366-1381.
36. Mania VM, Kallivokas AG, Malavaki C, Asimakopoulou AP, Kanakis J, Theocharis AD, Klironomos G, Gatzounis G, Mouzaki A, Panagiotopoulos E, Karamanos NK. 2009. A comparative biochemical analysis of glycosaminoglycans and proteoglycans in human orthotopic and heterothopic bone. IUBMB Life 61:447-452.
37. Manton KJ, Leong DFM, Cool SM, Nurcombe V. 2007. Disruption of heparan and chondroitin sulfate signaling enhances mesenchymal stem cell-derived osteogenic differentiation via bone morphogenetic protein signaling pathways. Stem Cells 25:2845-2854.
38. Miguez PA, Terajima M, Nagaoka H, Mochida Y, Yamauchi M. 2011. Role of glycosaminoglycans of biglycan in BMP-2 signaling. Biochem Biophys Res Comm 405:262-266.
39. Miyazaki T, Miyauchi S, Tawada A, Anada T, Matsuzaka S, Suzuki O. 2008. Oversulfated chondroitin sulfate-E binds to BMP-4 and enhances osteoblast differentiation. J Cell Physiol 217:769-777.
40. Miyazaki T, Miyauchi S, Tawada A, Anada T, Suzuki O. 2010. Effect of chondroitin sulfate-E on the osteoclastic differentiation of RAW264 cells. Dental Mat J 29:403-410.
41. Miyazono K, Kamiya Y, Morikawa M. 2010. Bone morphogenetic protein receptors and signal transduction. J Biochem 147:35-51.
42. Nesti LJ, Caterson EJ, Li W-J, Chang R, McCann TD, Hoek JB, Tuan RS. 2007. TGF-β1 calcium signaling in osteoblasts. J Cell Biochem 101:348-359.
43. Noda M, Rodan GA. 1989. Type beta transforming growth factor regulates expression of genes encoding bone matrix proteins. Connect Tissue Res 21:71-75.
44. Oswald J, Boxberger S, Jørgensen B, Feldmann S, Ehninger G, Bornhäuser M, Werner C. 2004. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 22:377-384.
45. Pichert A, Samsonov SA, Theisgen S, Thomas L, Baumann L, Schiller J, Beck-Sickinger AG, Huster D, Pisabarro MT. 2012. Characterization of the interaction of interleukin-8 with hyaluronan, chondroitin sulfate, dermatan sulfate and their sulfated derivatives by spectroscopy and molecular modeling. Glycobiology 22:134-145.
46. Pittenger MF. 2008. Mesenchymal stem cells from adult bone marrow. Methods Mol Biol 449:27-44.
47. Rai B, Nurvombe V, Cool SM. 2011. Heparan sulfate-based treatments for regenerative medicine. Crit Rev Eukaryot Gene Expr 21:1-12.
48. Rider CC. 2006. Heparin/heparan sulfate binding in the TGF-beta cytokine superfamily. Biochem Soc Trans 34:458-460.
49. Ross S, Hill CS. 2008. How the Smads regulate transcription. Int J Biochem Cell Biol 40:383-408.
50. Ruppert R, Hoffmann E, Sebald W. 1996. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological sctivity. Eur J Biochem 237:295-302.
51. Salbach J, Rachner TD, Rauner M, Hempel U, Anderegg U, Franz S, Simon J-C, Hofbauer LC. 2012. Regenerative potential of glycosaminoglycans for skin and bone. J Mol Med DOI: 10.1007/s00109-011-0843-2.
52. Sato MM, Nakashima A, Nashimoto M, Yawaka Y, Tamura M. 2009. Bone morphogenetic protein-2 enhances Wnt/β-catenin signaling-induced osteoprotegerin expression. Genes Cells 14:141-153.
53. Seib FP, Franke M, Jing D, Werner C, Bornhäuser M. 2009. Endogenous bone morphogenetic proteins in human boen marrow-derived multipotent mesenchymal stromal cells. Eur J Cell Biol 88:257-271.
54. Spinella-Jaegele S, Roman-Roman S, Faucheu C, Dunn F-W, Kawai S, Galléa S, Stiot V, Blanchet AM, Courtois B, Baron R, Rawadi G. 2001. Opposite effects of bone morphogenetic protein-2 and transforming growth factor-β1 on osteoblast differentiation. Bone 29:323-330.
55. Stadlinger B, Hintze V, Bierbaum S, Möller S, Schulz MC, Mai R, Kuhlisch E, Heinemann S, Scharnweber D, Schnabelrauch M, Eckelt U. 2012. Biological functionalization of dental implants with collagen and glycosaminoglycans--A comparative study. J Biomed Mater Res Part B: Appl Biomater 100B:331-341.
56. Takada T, Katagiri T, Ifuku M, Morimura N, Kobayashi M, Hasegawa A, Ogamo A, Kamijo R. 2003. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. J Biol Chem 278:43229-43235.
57. Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, Zhao L, Nagy TR, Peng X, Hu J, Hul WV, Wan M, Cao X. 2009. TGF-β1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 7:757-765.
58. Ten Dijke P, Hill CS. 2004. New insights into TGF-β-Smad signalling. Trends Biochem Sci 5:265-273.
59. Théoleyre S, Tat SK, Vusio P, Blanchard F, Gallagher J, Ricard-Blum S, Fortun Y, Padrines M, Rédini F, Heymann D. 2006. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: Role in the interaction with receptor activator of nuclear factor κB ligand (RANKL) and RANK. Biochem Biophys Res Comm 347:460-467.
60. Van der Smissen A, Hintze V, Scharnweber D, Möller S, Schnabelrauch M, Majok A, Simon JC, Anderegg U. 2011. Growth promoting substrates for human dermal fibroblasts provided by artificial extracellular matrices composed of collagen I and sulfated glycosaminoglycans. Biomaterials 32:8938-8946.
61. Yang HS, La WG, Bhang SH, Jeong-Yi J, Lee JH, Kim BS. 2010. Heparin-conjugated fibrin as an injectable system for sustained delivery of bone morphogenetic protein-2. Tissue Eng Part A 16:1225-1233.
62. Zhao B, Katagiri T, Toyoda H, Takada T, Yanai T, Fukuda T, Chung U, Koike T, Takaoka K, Kamijo R. 2006. Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J Biol Chem 281:23246-23253.